239 related articles for article (PubMed ID: 20731678)
1. The use of human immunodeficiency virus resistance tests in clinical practice.
Ceccherini-Silberstein F; Cento V; Calvez V; Perno CF
Clin Microbiol Infect; 2010 Oct; 16(10):1511-7. PubMed ID: 20731678
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. Development and performance of conventional HIV-1 phenotyping (Antivirogram®) and genotype-based calculated phenotyping assay (virco®TYPE HIV-1) on protease and reverse transcriptase genes to evaluate drug resistance.
Pattery T; Verlinden Y; De Wolf H; Nauwelaers D; Van Baelen K; Van Houtte M; Mc Kenna P; Villacian J
Intervirology; 2012; 55(2):138-46. PubMed ID: 22286884
[TBL] [Abstract][Full Text] [Related]
4. Genotypic resistance tests in the management of the HIV-infected patient at virological failure.
Aceti A; Carosi G
Scand J Infect Dis Suppl; 2003; 106():61-6. PubMed ID: 15000587
[TBL] [Abstract][Full Text] [Related]
5. Genotypic resistance tests for the clinical management of patients with primary HIV infection.
Narciso P; Lazzarin A
Scand J Infect Dis Suppl; 2003; 106():66-70. PubMed ID: 15000588
[TBL] [Abstract][Full Text] [Related]
6. Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution.
Johnson JA; Geretti AM
J Antimicrob Chemother; 2010 Jul; 65(7):1322-6. PubMed ID: 20466851
[TBL] [Abstract][Full Text] [Related]
7. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy.
Hanna GJ; D'Aquila RT
Clin Infect Dis; 2001 Mar; 32(5):774-82. PubMed ID: 11229846
[TBL] [Abstract][Full Text] [Related]
8. Genotypic resistance tests for the management of structured therapeutic interruptions after multiple drug failure.
Montroni M; Monforte AD
Scand J Infect Dis Suppl; 2003; 106():79-81. PubMed ID: 15000591
[TBL] [Abstract][Full Text] [Related]
9. Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel.
Hirsch MS; Brun-Vézinet F; Clotet B; Conway B; Kuritzkes DR; D'Aquila RT; Demeter LM; Hammer SM; Johnson VA; Loveday C; Mellors JW; Richman DD;
Top HIV Med; 2003; 11(4):150-4. PubMed ID: 12876334
[TBL] [Abstract][Full Text] [Related]
10. Genotypic resistance tests for the management of the HIV-infected pregnant woman.
Bassetti D; Cargnel A
Scand J Infect Dis Suppl; 2003; 106():70-4. PubMed ID: 15000589
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.
Hirsch MS; Günthard HF; Schapiro JM; Brun-Vézinet F; Clotet B; Hammer SM; Johnson VA; Kuritzkes DR; Mellors JW; Pillay D; Yeni PG; Jacobsen DM; Richman DD
Clin Infect Dis; 2008 Jul; 47(2):266-85. PubMed ID: 18549313
[TBL] [Abstract][Full Text] [Related]
12. Ultradeep sequencing in the therapeutic management of HIV-1 infection at treatment initiation.
Todesco E; Mercier-Darty M; Jung M; Bottero J; Boyd A; Marcelin AG; Calvez V; Morand-Joubert L
J Antimicrob Chemother; 2015; 70(6):1919-20. PubMed ID: 25637517
[No Abstract] [Full Text] [Related]
13. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
Zolopa AR
J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
[TBL] [Abstract][Full Text] [Related]
14. New insights into HIV resistance testing: nursing guidelines and implications.
Kirton CA; Kurtyka D; Sterken DJ
J Assoc Nurses AIDS Care; 2007; 18(3):74-86. PubMed ID: 17570302
[TBL] [Abstract][Full Text] [Related]
15. Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.
Haupts S; Ledergerber B; Böni J; Schüpbach J; Kronenberg A; Opravil M; Flepp M; Speck RF; Grube C; Rentsch K; Weber R; Günthard HF;
Antivir Ther; 2003 Oct; 8(5):443-54. PubMed ID: 14640392
[TBL] [Abstract][Full Text] [Related]
16. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Cabrera C; Cozzi-Lepri A; Phillips AN; Loveday C; Kirk O; Ait-Khaled M; Reiss P; Kjaer J; Ledergerber B; Lundgren JD; Clotet B; Ruiz L;
Antivir Ther; 2004 Oct; 9(5):787-800. PubMed ID: 15535417
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of testing human immunodeficiency virus for drug resistance.
Harrigan PR; Côté HC
Clin Infect Dis; 2000 Jun; 30 Suppl 2():S117-22. PubMed ID: 10860895
[TBL] [Abstract][Full Text] [Related]
18. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
[TBL] [Abstract][Full Text] [Related]
19. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
[TBL] [Abstract][Full Text] [Related]
20. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
